Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 15

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 15
---
 Assuming that we receive
net proceeds of approximately $3.4 million from this offering (assuming an offering with gross proceeds of $4 million),
we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs
through the end of February 2026 under our current business plan. Assuming that we receive net proceeds of approximately
$2.5 million from this offering (assuming an offering with gross proceeds of $3 million), we believe that the net proceeds
from this offering, together with our existing cash and cash equivalents, will satisfy our capital needs through the end of January
2026 under our current business plan. Without giving effect to the receipt of any proceeds from this offering, we currently estimate
that our existing cash and cash equivalents are sufficient to fund business operations into November 2025.

| 6 |

If we are required to obtain Warrant Stockholder Approval, until we are able to receive such approval the Common Warrants will not be exercisable, and if we are unable to obtain such approval the Common Warrants will have no value.

The common warrants
will have an exercise price of $ per share and will be exercisable beginning on the Warrant Stockholder Approval Date; provided,
however, if the Pricing Conditions are met, the common warrants will be exercisable upon issuance. The Series A common warrants
and Series B common warrants will expire on the 5 anniversary and 18-month anniversary, respectively, of the
Warrant Stockholder Approval Date, provided that if the Pricing Conditions are met, the Series A common warrants and Series B
common warrants will expire on the five-year anniversary and 18-month anniversary, respectively, of the date of issuance.

If we are required
to obtain Warrant Stockholder Approval, the common warrants will not be exercisable until, and unless, we obtain the Warrant Stockholder
Approval from our stockholders. While we intend to promptly seek the Warrant Stockholder Approval, if required, there is no guarantee
that the Warrant Stockholder Approval will ever be obtained. If we are unable to obtain the Warrant Stockholder Approval, the common
warrants will have no value. In addition, we will incur substantial cost, and management will devote substantial time and attention,
in attempting to obtain the Warrant Stockholder Approval.

Our management team will have immediate and broad discretion over the use of the net proceeds from this offering and may not use them effectively.

We currently intend to use the net proceeds of this offering